SPY312.23+1.71 0.55%
DIA258.42+1.11 0.43%
IXIC10,207.63+53.00 0.52%

Anchinao Therapeutics Reports Discontinues Phase 2 Codex Study Of Inodiftagene Vixteplasmid In Patients With Non-Muscle-Invasive Bladder Cancer

Benzinga · -